Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry

• Published in: Analytical and bioanalytical chemistry 2007-01, Vol.387 (2), p.593-601
• Main Authors: Kolocouri, Filomila, Dotsikas, Yannis, Apostolou, Constantinos, Kousoulos, Constantinos, Loukas, Yannis L
• Format: Article
• Language: English
• Subjects: 96 deep well; Antihypertensive Agents - blood; Chemical Fractionation; Drug Combinations; Drug Monitoring - methods; Humans; hydrochlorothiazide; Hydrochlorothiazide - administration & dosage; Hydrochlorothiazide - blood; Imidazoles - administration & dosage; Imidazoles - blood; Losartan; Losartan - administration & dosage; Losartan - blood; mass spectrometry; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tetrazoles - administration & dosage; Tetrazoles - blood
• ISSN: 1618-2642; 1618-2650
• DOI: 10.1007/s00216-006-0990-4

An automated, sensitive and high-throughput liquid chromatographic/electrospray tandem mass spectrometric (LC-MS/MS) assay was developed for the simultaneous determination of losartan (LOS), its major circulating metabolite EXP-3174 and hydrochlorothiazide (HCTZ) in human plasma. LOS and HCTZ coexist in the same drug formulation, and this is the first method that enables the simultaneous determination of both drugs along with the active metabolite of LOS. Since these drugs have different physicochemical properties, the employment of a liquid-liquid extraction (LLE) protocol was precluded. A fully automated solid-phase extraction (SPE) protocol, based on 96-well format plates, was used to isolate these compounds and furosemide (internal standard, IS) from plasma. Washing and elution steps were amended accordingly in order to minimize any matrix effect from components of the plasma without reducing the elution of the molecules of interest. The compounds were eluted from a C18 column and detected with an API 3000 triple-quadrupole mass spectrometer using negative electrospray ionization and multiple reaction monitoring (MRM). The assay was linear over the range 1.00-400 ng/mL for LOS and EXP-3174 and 0.500-200 ng/mL for HCTZ, respectively, when 200 μl of plasma was used in the extraction. The overall intra- and interassay variations were within acceptance limits. The analysis time for each sample was 4 min, and more than 300 samples could be analyzed in one day by running the system overnight. The assay was simple, highly sensitive, selective, precise, fast, and it enables the reliable determination of LOS, EXP-3174 and HCTZ in pharmacokinetic or bioequivalence studies after per os administration of a single tablet containing both drugs.